Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 4

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis

Authors Noll Campbell, Amir Ayub, Malaz A Boustani, Chris Fox, Martin Farlow, et al

Published Date October 2008 Volume 2008:3(4) Pages 719—728

DOI http://dx.doi.org/10.2147/CIA.S4250

Published 13 October 2008

Noll Campbell1, Amir Ayub2, Malaz A Boustani2, Chris Fox3, Martin Farlow4, Ian Maidment3, Robert Howard5

1Wishard Health Services, Indianapolis, Indiana; 2Indiana University Center for Aging Research, Regenstrief Institute, Inc., Indianapolis, Indiana; 3University of Kent, Kent, United Kingdom; 4Indiana University School of Medicine, Indianapolis, Indiana; 5King’s College, London, United Kingdom

Objective: To determine the efficacy of cholinesterase inhibitors (ChEIs) in improving the behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer’s disease (AD).

Data sources: We searched MEDLINE, Cochrane Registry, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) from 1966 to 2007. We limited our search to English Language, full text, published articles and human studies.

Data extraction: We included randomized, double-blind, placebo-controlled trials evaluating the efficacy of donepezil, rivastigmine, or galantamine in managing BPSD displayed by AD patients. Using the United States Preventive Services Task Force (USPSTF) guidelines, we critically appraised all studies and included only those with an attrition rate of less than 40%, concealed measurement of the outcomes, and intention to treat analysis of the collected data. All data were imputed into pre-defined evidence based tables and were pooled using the Review Manager 4.2.1 software for data synthesis.

Results: We found 12 studies that met our inclusion criteria but only nine of them provided sufficient data for the meta-analysis. Among patients with mild to severe AD and in comparison to placebo, ChEIs as a class had a beneficial effects on reducing BPSD with a standard mean difference (SMD) of −0.10 (95% confidence interval [CI]; −0.18, −0.01) and a weighted mean difference (WMD) of −1.38 neuropsychiatry inventory point (95% CI; −2.30, −0.46). In studies with mild AD patients, the WMD was −1.92 (95% CI; −3.18, −0.66); and in studies with severe AD patients, the WMD was −0.06 (95% CI; −2.12, +0.57).

Conclusion: Cholinesterase inhibitors lead to a statistical significant reduction in BPSD among patients with AD, yet the clinical relevance of this effect remains unclear.

Keywords: Alzheimer’s disease, dementia, cholinesterase inhibitors, behavioral and psychological symptoms

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Selecting a change and evaluating its impact on the performance of a complex adaptive health care delivery system

Malaz A Boustani, Stephanie Munger, Rajesh Gulati, et al

Clinical Interventions in Aging 2010, 5:141-148

Published Date: 5 May 2010

The cognitive impact of anticholinergics: A clinical review

Noll Campbell, Malaz Boustani, Tony Limbil, Carol Ott, et al.

Clinical Interventions in Aging 2009, 4:225-233

Published Date: 13 May 2009

The challenge of supporting care for dementia in primary care

Malaz Boustani, Cathy Schubert, Youcef Sennour

Clinical Interventions in Aging 2007, 2:631-636

Published Date: 3 January 2007

Readers of this article also read:

Corneal sensitivity after topical bromfenac sodium eye-drop instillation

Yanai K, Huang J, Kadonosono K, Uchio E

Clinical Ophthalmology 2013, 7:741-744

Published Date: 17 April 2013

Glaucoma associated with the management of rhegmatogenous retinal detachment

Mangouritsas G, Mourtzoukos S, Portaliou DM, Georgopoulos VI, Dimopoulou A, Feretis E

Clinical Ophthalmology 2013, 7:727-734

Published Date: 15 April 2013

Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations

Fukuda M, Shibata S, Shibata N, Hagihara K, Yaguchi H, Osada H, Takahashi N, Kubo E, Sasaki H

Clinical Ophthalmology 2013, 7:515-520

Published Date: 12 March 2013

Cubic phase nanoparticles for sustained release of ibuprofen formulation characterization and enhanced bioavailability study

Dian L, Yang Z, Li F, Wang Z, Pan X, Peng X, Huang X, Guo Z, Quan G, Shi X, Chen B, Li G, Wu C

International Journal of Nanomedicine 2013, 8:845-854

Published Date: 26 February 2013

Connecting research discovery with care delivery in dementia: the development of the Indianapolis Discovery Network for Dementia

Boustani MA, Frame A, Munger S, Healey P, Westlund J, Farlow M, Hake A, Austrom MG, Shepard P, Bubp C, Azar J, Nazir A, Adams N, Campbell NL, Chehresa A, Dexter P

Clinical Interventions in Aging 2012, 7:509-516

Published Date: 16 November 2012

Oxybutynin reduces sweating in depressed patients treated with sertraline: a double-blind, placebo-controlled, clinical study

Ghaleiha A, Jahangard L, Sherafat Z, Ahmadpanah M, Brand S, Holsboer-Trachsler E, Bajoghli H, Haghighi M

Neuropsychiatric Disease and Treatment 2012, 8:407-412

Published Date: 14 September 2012

Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study

Eton DT, Ramalho de Oliveira D, Egginton JS, Ridgeway JL, Odell L, May CR, Montori VM

Patient Related Outcome Measures 2012, 3:39-49

Published Date: 24 August 2012

Lack of information and access to advanced treatment for Parkinson’s disease patients

Lökk J

Journal of Multidisciplinary Healthcare 2011, 4:433-439

Published Date: 13 December 2011

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong

Werner Poewe, Angelo Antonini, Jan CM Zijlmans, et al

Clinical Interventions in Aging 2010, 5:229-238

Published Date: 25 August 2010